Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:1978
|
| gptkbp:atccode |
L01 XA02
|
| gptkbp:brand |
gptkb:Paraplatin
|
| gptkbp:chemical_formula |
C6 H10 N2 O4 Pt
|
| gptkbp:class |
gptkb:Agent
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:clinical_use |
combination therapy
monotherapy |
| gptkbp:compatibility |
certain IV solutions
|
| gptkbp:contraindication |
severe bone marrow suppression
hypersensitivity to carboplatin |
| gptkbp:counseling_services |
monitor for signs of infection
avoid pregnancy during treatment report unusual bleeding or bruising hydration recommended |
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:effective_date |
FDA approved
EMA approved |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
sterile solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Carboplatin Teva
|
| gptkbp:indication |
gptkb:Oncology
ovarian cancer |
| gptkbp:ingredients |
gptkb:carboplatin
|
| gptkbp:interacts_with |
live vaccines
other nephrotoxic drugs |
| gptkbp:is_monitored_by |
renal function
|
| gptkbp:lifespan |
3 to 6 hours
|
| gptkbp:manufacturer |
gptkb:Teva_Pharmaceuticals
|
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:metabolism |
minimal hepatic metabolism
|
| gptkbp:packaging |
vial
|
| gptkbp:pharmacokinetics |
dose-dependent clearance
DNA cross-linking agent |
| gptkbp:research |
ongoing clinical trials
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:route_of_elimination |
renal
|
| gptkbp:safety |
pregnancy category D
lactation caution elderly caution monitor for renal toxicity pediatric use not established |
| gptkbp:shelf_life |
36 months
|
| gptkbp:side_effect |
gptkb:anemia
nausea vomiting thrombocytopenia bone marrow suppression neutropenia |
| gptkbp:storage |
room temperature
|
| gptkbp:structure |
platinum-based compound
|
| gptkbp:used_for |
treating cancer
|
| gptkbp:bfsParent |
gptkb:carboplatin
|
| gptkbp:bfsLayer |
6
|